Ladiratuzumab manufacturers
- Ladiratuzumab
-
- $263.00
-
2026-07-28
- CAS:1629760-28-6
- Purity: 95.00%
- Supply Ability: 10g
|
| | Ladiratuzumab Basic information |
| Product Name: | Ladiratuzumab | | Synonyms: | Ladiratuzumab;Research Grade Ladiratuzumab (DHG52901);Research Grade Ladiratuzumab;Ladiratuzumab (anti-SLC39A6);hLIV22 | | CAS: | 1629760-28-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Ladiratuzumab Structure]() |
| | Ladiratuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Ladiratuzumab Usage And Synthesis |
| Uses | Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC)[1][2]. | | References | [1] Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. DOI:10.1016/j.pharmthera.2017.07.013
[2] Cao, et al. Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Research 78.13_Supplement (2018): 2742-2742. |
| | Ladiratuzumab Preparation Products And Raw materials |
|